Novel targeting of therapy-resistant prostate cancer cells.

针对治疗耐药的前列腺癌细胞的新靶向。

• 批准号: nhmrc : GNT1140222
• 负责人: A/Pr Arun Azad
• 金额: $ 59.7万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-targeting-therapy-cancer-cells/1348288
• 关键词: Novel; targeting; therapy; resistant; prostate

Prostate cancer is treated by removing male hormones (androgens). Although the bulk of the tumour regresses, some cells remain and the cancer often grows back in an aggressive form. We will study new ways to eliminate therapy resistant cancer cells and thereby provide more lasting treatments for prostate cancer. Ultimately, we hope to inform the design of ground-breaking clinical trials that could re-shape the treatment paradigm of advanced prostate cancer.

前列腺癌是通过去除男性激素（雄激素）来治疗的。虽然大部分肿瘤消退，但仍有一些细胞存在，癌症通常以侵袭性形式重新生长。我们将研究消除耐药癌细胞的新方法，从而为前列腺癌提供更持久的治疗方法。最终，我们希望为突破性临床试验的设计提供信息，这些临床试验可以重新塑造晚期前列腺癌的治疗模式。